3026597-15-6
Chemical Structure
DN-1289
- CAS No.: 3026597-15-6
- Formula:C18H19F4N7O2
- Molecular Weight:441.38
IUPAC Name: 5-(2-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-6-(3,3-difluoropyrrolidin-1-yl)pyrimidin-4-yl)-3-(difluoromethoxy)pyrazin-2-amine
InChIKey: AVWDJSXSWJBVBP-UWVGGRQHSA-N
SMILES: NC1=C(OC(F)F)N=C(C2=NC(N3[C@@H](C4)CO[C@@H]4C3)=NC(N5CCC(F)(F)C5)=C2)C=N1
Biological Activity: DN-1289 is an orally active and selective inhibitor of dual leucine zipper kinase (DLK; IC50=17 nM) and leucine zipper-bearing kinase (LZK; IC50=40 nM). DN-1289 results significant attenuation of optic nerve crush (ONC)-induced p-c-Jun in mice model. DN-1289 has excellent in vivo plasma half-life and blood-brain barrier permeability[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DN-1289 | 99.63% | DN-1289 is an orally active and selective inhibitor of dual leucine zipper kinase (DLK; IC50=17 nM) and leucine zipper-bearing kinase (LZK; IC50=40 nM). DN-1289 results significant attenuation of optic nerve crush (ONC)-induced p-c-Jun in mice model. DN-1289 has excellent in vivo plasma half-life and blood-brain barrier permeability. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
